Sinobiomed Inc. will begin a Phase II clinical trial of its malaria vaccine candidate, PfCP2.9, in Thailand in Q3 2008. Thailand is currently experiencing a malaria epidemic. In its Phase I trial, which was completed in 2004, PfCP2.9 generated a strong immune response with only mild side effects. In January 2008, Sinobiomed was awarded a 9 million RMB ($1.2 million) government grant for PfCP2.9 as part of China’s 863 Program that encourages technologically innovative products. More details...

Stock Symbol: (OTCBB: SOBM)